Skip to main content Start main content

CSL Research Acceleration Initiative (Call for Proposal)



CSL is a global biotechnology company with headquarter in Australia that develops and delivers innovative biotherapies. The company’s Research Acceleration Initiative (RAI) aims to explore partnerships on novel biotherapeutic strategies in CSL’s therapeutic areas, with funding up to USD200k per year for up to 2 years.

The 2023 RAI focuses on research proposals that align with a CSL therapeutic areas and are amenable to or include a modality. More details can be found at Gloabl RAI 2023 Scientific Flyer and Information Session Deck. Researchers who wish to apply are required to submit a non-confidential, 300 word abstract by 23 February 2023 9am HKT to Research and Innovation Office (RIO).


Please visit CSL's website for more details.

Your browser is not the latest version. If you continue to browse our website, Some pages may not function properly.

You are recommended to upgrade to a newer version or switch to a different browser. A list of the web browsers that we support can be found here